These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 26480701)

  • 21. Melanoma during fingolimod treatment for multiple sclerosis.
    Velter C; Thomas M; Cavalcanti A; Bastien M; Chochon F; Lubetzki C; Routier E; Robert C
    Eur J Cancer; 2019 May; 113():75-77. PubMed ID: 30986706
    [No Abstract]   [Full Text] [Related]  

  • 22. [Switching therapy from natalizumab to fingolimod: reduction of the washout time?].
    Sánchez-Gundín J; Flor García A; Martí Gil C; Gómez Romero L
    Farm Hosp; 2015 Sep; 39(5):314-5. PubMed ID: 26546944
    [No Abstract]   [Full Text] [Related]  

  • 23. Primary Cutaneous Cryptococcus in a Patient With Multiple Sclerosis Treated With Fingolimod.
    Forrestel AK; Modi BG; Longworth S; Wilck MB; Micheletti RG
    JAMA Neurol; 2016 Mar; 73(3):355-6. PubMed ID: 26751160
    [No Abstract]   [Full Text] [Related]  

  • 24. Fingolimod Prescribed for the Treatment of Multiple Sclerosis in Patients Younger Than Age 18 Years.
    Fragoso YD; Alves-Leon SV; Barreira AA; Callegaro D; Brito Ferreira ML; Finkelsztejn A; Gomes S; Magno Goncalves MV; Moraes Machado MI; Marques VD; Cunha Matta AP; Papais-Alvarenga RM; Apostolos Pereira SL; Tauil CB
    Pediatr Neurol; 2015 Aug; 53(2):166-8. PubMed ID: 26026897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of fingolimod in clinical practice: The experience of an academic center in the Middle East.
    Yamout BI; Zeineddine MM; Tamim H; Khoury SJ
    J Neuroimmunol; 2015 Dec; 289():93-7. PubMed ID: 26616877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Severe Exacerbation of Multiple Sclerosis Following Withdrawal of Fingolimod.
    Fragoso YD; Adoni T; Gomes S; Goncalves MVM; Parolin LF; Rosa G; Ruocco HH
    Clin Drug Investig; 2019 Sep; 39(9):909-913. PubMed ID: 31152369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Five cases of malignant melanoma during fingolimod treatment in Dutch patients with MS.
    Killestein J; Leurs CE; Hoogervorst ELJ; van Eijk J; Mostert JP; van den Eertwegh AJM; Uitdehaag BMJ
    Neurology; 2017 Aug; 89(9):970-972. PubMed ID: 28768850
    [No Abstract]   [Full Text] [Related]  

  • 28. Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab.
    Bernard-Valnet R; Pignolet B; Biotti D; Ciron J; Lafontan JF; Dumas H; Bonneville F; Brassat D
    Mult Scler Relat Disord; 2018 Oct; 25():216-218. PubMed ID: 30114625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question.
    Pistono C; Osera C; Boiocchi C; Mallucci G; Cuccia M; Bergamaschi R; Pascale A
    Pharmacol Res; 2017 Jun; 120():279-293. PubMed ID: 28396093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cutaneous anaplastic large cell lymphoma in a multiple sclerosis patient receiving Fingolimod.
    Manouchehri N; Mirmosayyeb O; Badihian S; Shaygannejad V
    Mult Scler Relat Disord; 2018 Jan; 19():121-123. PubMed ID: 29195114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Fingolimod-Treatment on Blood Lipid Profiles of Multiple Sclerosis Patients.
    Hovi A; Airas L
    J Neuroimmune Pharmacol; 2016 Dec; 11(4):611-612. PubMed ID: 27388874
    [No Abstract]   [Full Text] [Related]  

  • 32. Cerebral toxoplasmosis in an MS patient receiving Fingolimod.
    Enriquez-Marulanda A; Valderrama-Chaparro J; Parrado L; Diego Vélez J; Maria Granados A; Luis Orozco J; Quiñones J
    Mult Scler Relat Disord; 2017 Nov; 18():106-108. PubMed ID: 29141790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod.
    Stitt DW; Boes CJ; Flanagan EP; Howard MT; Colgan JP
    Mult Scler Relat Disord; 2018 Jan; 19():115-117. PubMed ID: 29190574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment.
    Bianco A; Patanella AK; Nociti V; De Fino C; Lucchini M; Savio FL; Rossini PM; Mirabella M
    Mult Scler Relat Disord; 2016 Sep; 9():11-3. PubMed ID: 27645336
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence and Risk of Infection Associated With Fingolimod in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis of 8,448 Patients From 12 Randomized Controlled Trials.
    Zhao Z; Ma CL; Gu ZC; Dong Y; Lv Y; Zhong MK
    Front Immunol; 2021; 12():611711. PubMed ID: 33763062
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of dosage reduction on peripheral blood lymphocyte count in patients with multiple sclerosis receiving long-term fingolimod therapy.
    Takahashi K
    J Clin Neurosci; 2019 May; 63():91-94. PubMed ID: 30772201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis.
    Blumenfeld S; Staun-Ram E; Miller A
    J Autoimmun; 2016 Jun; 70():40-51. PubMed ID: 27055778
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency and clinical characteristics of Multiple Sclerosis rebounds after withdrawal of Fingolimod.
    Evangelopoulos ME; Miclea A; Schrewe L; Briner M; Salmen A; Engelhardt B; Huwiler A; Chan A; Hoepner R
    CNS Neurosci Ther; 2018 Oct; 24(10):984-986. PubMed ID: 29898493
    [No Abstract]   [Full Text] [Related]  

  • 39. Severe aseptic temporal lobe encephalitis on fingolimod.
    Rotstein DL; Bharatha A; Selchen D
    Mult Scler Relat Disord; 2018 Jul; 23():4-6. PubMed ID: 29689473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disease-modifying therapies and infectious risks in multiple sclerosis.
    Winkelmann A; Loebermann M; Reisinger EC; Hartung HP; Zettl UK
    Nat Rev Neurol; 2016 Apr; 12(4):217-33. PubMed ID: 26943779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.